The rise and fall of the thiazolidinediones: Impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 20, Issue 3, 2013, Pages

  Hashim, Salman ^a   Gomes, Tara ^b,c   Juurlink, David ^b,d,e   Hellings, Chelsea ^b   Mamdani, Muhammad ^c,e  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Diabetes; Drug policy; Drug utilization; Pharmacoepidemiology

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DATA BASE; DRUG FORMULARY; DRUG SAFETY; DRUG UTILIZATION; HEALTH CARE POLICY; HUMAN; INCIDENCE; PRESCRIPTION; PUBLICATION; REIMBURSEMENT;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; EVIDENCE-BASED MEDICINE; FEMALE; FORMULARIES AS TOPIC; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; META-ANALYSIS AS TOPIC; ONTARIO; POPULATION SURVEILLANCE; THIAZOLIDINEDIONES;

EID: 84884293248     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. Impact of clinical trial results on national trends in a-blocker prescribing, 1996-2002. JAMA 2004;291(1):54-62.
2. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007;298.1:61-69.
3. Hollon MF. Direct-to-consumer marketing of prescription drugs. JAMA 1999;281.4:382-384.
4. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. The Lancet 2005;366:1279-1289.
5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
6. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011;11(2):115-128.
7. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander C, Jackevicius CA. Responding to an FDA warning-geographic variation in the use of rosiglitazone. N Engl J Med 2010;363:2081-2084.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
9. US Department of Health and Human Services: US Food and Drug Administration: FDA significantly restricts access to the diabetes drug Avandia [article online], 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm Accessed 30 March 2011
10. European Medicines Agency: Questions and answers on the suspension of rosiglitazone-containing medicines, Sept 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/09/WC500097003.pdf
11. Ministry of Health and Long-Term Care: Change in Funding Status Rosiglitazone (Avandia®) and Pioglitazone (Actos® and Generics). Ontario Public Drug Programs.
12. Ministry of Health and Long-Term Care. Exceptional Access Program, Telephone Request Service: Reimbursement Criteria, Sept 2011. Available from: http://www.health.gov.on.ca/english/public/pub/drugs/trs/trs_guide.pdf
13. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008; Jul-Aug;14(6):523-31.
14. Stewart KA, Natzke BM, Williams T, Granger E, Casscells SW, Croghan TW. Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone. Pharmacoepidemiol Drug Saf 2009 Nov;18(11):1048-52.
15. Shi L, Zhao Y, Szymanski K, Yau L, Fonseca V. Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. J Diabetes Complications 2011;May-Jun 25(3):143-50.
16. Jain R, Mullins CD, Lee H, Wong W. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. Res Social Adm Pharm 2012 Jan;8(1):47-59.
17. Morrow RL, Carney G, Wright JM, Bassett K, Sutherland J, Dormuth CR. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open Med 2010;4(1):e50-9.
18. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning--geographic variation in the use of rosiglitazone. N Engl J Med 2010 Nov 25;363(22):2081-4.
19. Shah BR, Juurlink DN, Austin PC, Mamdani MM. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Diabet Med 2008 Jul;25(7):871-4.
20. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10:67-71.
21. Statistics Canada. Percentage of the Population aged 65 years and over-Ontario Censuses, 2009. Available from: http://www12.statcan.gc.ca/census-recensement/2006/dp-pd/92-596/figure1.cfm?STID=203&Lang=eng&T=PR&PRCODE=35&GEOCODE=35&GEOLVL=PR&TID=0. Accessed on September 2011.
22. Pindyck RS, Rubinfeld DL. Econometric models and economic forecasts. Boston: Irwin/McGraw-Hill, 1998.
23. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349:2224-2232.
24. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351(6):543-51.
25. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med 2003;115:467-72.
26. Beatriz CC, Rubinstein A. Influence of new evidence on prescription patterns. J Am Board Fam Pract 2002;15:457-62.